Profil bibliographique

P Schmid

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

18Publications signalées

11Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

Advanced Breast Cancer TherapiesHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesCancer Treatment and PharmacologyCancer Immunotherapy and Biomarkers

Les publications récentes

Accès ouvert 2026 article OpenAlex

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

P Schmid, Seock-Ah Im, Z Nowecki, Piotr J. Wysocki et autres

gb, kr, pl, us (code pays fourni par la source)

2 citations Nature Cancer

2026 article OpenAlex

Progression-free survival after next line of treatment (PFS2) and subsequent therapies (subs tx) in the ASCENT-04 study of participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs chemotherapy (chemo) plus pembro.

Kevin Kalinsky, P Schmid, Evandro de Azambuja, S Loi et autres

us, gb, be, au, kr, Afrique du Sud, fr, ca, jp, mx, br (code pays fourni par la source)

2 citations Journal of Clinical Oncology

Accès ouvert 2026 conference-abstract OpenAlex

OPERA-02: A phase 3 study of palazestrant plus ribociclib as first-line treatment of ER+, HER2- advanced breast cancer.

Sara M. Tolaney, Giampaolo Bianchini, Virginia F. Borges, Eva Ciruelos et autres

us, it, es, kr, de, gb, fr (code pays fourni par la source)

1 citation Journal of Clinical Oncology

2026 conference-abstract OpenAlex

ReDiscover-2, a phase 3 study of zovegalisib (zovega, RLY-2608) + fulvestrant (fulv) versus capivasertib (capi) + fulv as treatment for locally advanced or metastatic PIK3CA -mutant HR+/ HER2- breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

H S Rugo, Cristina Saura, Komal L. Jhaveri, Carlos H. Barrios et autres

us, es, br, au, de, fr, kr, gb, it (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA -mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV).

N C Turner, Kevin Kalinsky, Katherine E. Hutchinson, Yanling Jin et autres

gb, us, ca, de, es, be, kr, au (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Time-of-day administration of immunotherapy in early-stage triple-negative breast cancer: Immune-dependent chronotherapy effects in the phase III A-BRAVE trial.

Maria Vittoria Dieci, Davide Massa, Elisa Gasparini, P Schmid et autres

it, gb (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.

S Loi, Erika P. Hamilton, Komal L. Jhaveri, C Anders et autres

au, us, gb, tw, es, br, it, tr, in, nl, pl, fr (code pays fourni par la source)

0 citations Journal of Clinical Oncology

Accès ouvert 2026 conference-abstract OpenAlex

ASCENT-04: Analysis of efficacy by biomarker subgroups with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in participants (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC).

Sara M. Tolaney, P Schmid, Evandro de Azambuja, Kevin Kalinsky et autres

us, gb, be, kr, Afrique du Sud, fr, ca, jp, mx, br, au (code pays fourni par la source)

0 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor–positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.

P Schmid, Charles E. Geyer, Maite Velázquez Martín, S Hurvitz et autres

gb, us, es, kr, jp, br, de, au, ar, tw, ch (code pays fourni par la source)

2 citations Journal of Clinical Oncology

2026 conference-abstract OpenAlex

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.

P Schmid, J Cortés, Rebecca Dent, Heather L. McArthur et autres

gb, es, sg, us, de, kr, au, jp, fr (code pays fourni par la source)

1 citation Journal of Clinical Oncology

2026 conference-abstract OpenAlex

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.

David W. Cescon, Tiffany A. Traina, P Schmid, J Cortes et autres

ca, us, gb, ch, cn, jp, kr, fr, mx, tr, es, Afrique du Sud, tw, it, nl, pl, sg (code pays fourni par la source)

3 citations Journal of Clinical Oncology

Accès ouvert 2026 article OpenAlex

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer

P Schmid, C X Ma, Yeon Hee Park, Simon Lord et autres

gb, us, kr, tw, ca, pl, dk, sg (code pays fourni par la source)

0 citations Clinical Cancer Research

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.